MEDTRONIC PLC
MDTNYSETrading Snapshot
- Day Range
- $93.06 โ $95.72
- 52-Week Range
- $73.31 โ $106.33
- Volume (shares)
- 9,578,572
- Avg Volume (shares)
- โ
- Shares Outstanding
- 1.28B
- Next Earnings
- 2026-11-24
Fundamentals Snapshot
- Annual Revenue
- $36.36B
- Last Q Revenue
- $9.76B
- P/E Ratio
- 23.3
- P/S Ratio
- 3.3x
- EPS (TTM)
- $4.06
- Dividend Yield
- 2.99%
- Dilution (1yr)
- โ0.2%
MEDTRONIC PLC
MDTAbout MEDTRONIC PLC
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Ratings
โLatest News & Updates

Medtronic: Broader Growth, Attractive Valuation
Medtronic is rated Buy, trading at a 20.8% P/E discount to sector median, with new products driving broader growth post-MiniMed separation. Pulsed field ablation (PFA) and enabling technologies in Cardiovascular and Spin

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could res

Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?
Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster.

A Look at Medtronic PLC (MDT) After 3.8% Gain -- GF Value $101.17 vs Price $96.59
On October 22, 2026, Medtronic PLC (MDT) shares rose 3.8% to a current price of $96.59. This movement comes amid a 52-week range of $73.31 to $106.33, indicatin

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtueยฎ SAB
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, โOrchestra BioMedโ or the โCompanyโ), a biomedical company accelerating high-impact technologies to patients through risk-re

Medtronic announces positive results from real-world registries for the Sphere-9โข catheter and PulseSelectโข PFA System at APHRS 2026
Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias Medtronic continues to strengthen its position in cardiac ablation, building on a legacy